Anti-inflammatory therapy that does not affect thrombosis or LDL-c, can beneficially impact arterial disease
Inflammation expert opinionsAug. 28, 2017 - ESC 2017, Barcelona, Spain
Video navigation menu
- The CANTOS trial was a ground-breaking trial for several reasons 0:30
- Inhibiting IL-1β also seems to reduce the rates of cancer mortality, incident lung cancer and lung cancer mortality 2:27
- Dose-response relation seen for cancer, but not for the CV benefit 3:12
- Multiple anti-inflammatory agents are being studied to further test the inflammation hypothesis 3:49
The CANTOS trial is the first in a series of trials that test the hypothesis that inhibiting inflammation can lower residual CV risk. The results of this trial indeed confirm this hypothesis, suggesting that from now on, targeting inflammation may need to be considered in patients on lipid-lowering therapy with residual inflammatory CV risk.
These inflammation expert opinion videos are aimed to provide guidance and perspectives on the implications of the CANTOS trial and other trials addressing inflammation in CVD. These expert views may help translate scientific findings to future clinical practice, by improving personalized CV risk management.
Philippe Gabriel Steg, MD - Hôpital Bichat, Paris, France
Funding to produce this video was provided by an unrestricted educational grant from Novartis.